A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

Trial Profile

A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2018

At a glance

  • Drugs NBTXR 3 (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PharmaEngine
  • Most Recent Events

    • 30 Mar 2018 According to a company media release, company will present an interim results from this study with high risk elderly patients in 2018.
    • 30 Mar 2018 According to a company media release, Nanobiotix filed a protocol amendment of this study to expand more patients to confirm the efficacy of NBTXR3. Company is planning to open 12-15 additional clinical trial sites in Europe and to expand this study to the U.S. at a later stage.
    • 09 Nov 2017 According to a company media release, Nanobiotix filed a protocol amendment of this study to include 44 additional patients. Nanobiotix is also opening 12-15 additional sites in Europe to expand the development of this indication.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top